Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening

Annals of Hematology

Volumn 83, Issue 7, 2004, Pages 430-433

  Alebouyeh, M ^a   Moussavi, F ^a   Haddad Deylami, H ^a   Vossough, P ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Genetic screening; Hydroxyurea; IVSII 1 mutation; Major thalassemia; Xmn1 polymorphism

Indexed keywords

FERRITIN; FOLIC ACID; HEMOGLOBIN F; HYDROXYUREA;

ADOLESCENT; ADULT; ARTICLE; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ERYTHROCYTE CONCENTRATE; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SCREENING; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MALE; OUTCOMES RESEARCH; PRIORITY JOURNAL; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATING AGENTS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DEFEROXAMINE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FACIAL BONES; FEMALE; GENETIC HETEROGENEITY; GENETIC SCREENING; GENOTYPE; GLOBINS; HUMANS; HYDROXYUREA; IRAN; MALE; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SPLENECTOMY;

EID: 3042772793     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0836-5     Document Type: Article

References (25)

1. Arruda VR, Lima CS, Saad ST, Costa FF (1997) Successful use of hydroxyurea in β-thalassaemia major. N Engl J Med 336:964
2. Blau CA, Stamatoynnopoulos G (1993) Evolving therapies in globin gene disorders. In: Lechner K, Gadner H (eds) Haematology trends '93 .Schattauer, New York, pp144-58
3. Bunn HF (1999) Induction of fetal hemoglobin in sickle cell disease. Blood 9:762
4. Cao A, Gatanello R, Rosatelli MC (1994) Genotype-phenotype correlations in β-thalassaemia. Blood Rev 8:1-12
5. Charache S (1991) Hydroxyurea as treatment for sickle cell anemia. Hematol Oncol Clin North Am 5:571-583
6. Choudhry VP, Lal A, Pati HP, Arya LS (1997) Hematological responses to hydroxyurea therapy in multitransfused thalassaemic children. Indian J Pediatr 64:395-398
7. Dedoussis GV, Mandilara GD, Boussiu M, Loutradis A (2000) Hb F production in beta thalassaemia heterozygotes for the IVSII-1 G→A beta(0) globin mutation. Implication of the haplotype and the (G)gamma-158 C→T mutation on the Hb F level. Am J Hematol 64:151-155
8. Dover GJ (1998) Hemoglobin switching protocols in thalassaemia. Experience with sodium phenylbutyrate and hydroxyurea. Ann N Y Acad Sci 850:80-86
9. Fucharoen S, Siritanaratkul N, Winichagoon P, Chowthaworn J, Siriboon W, Muangsup W, Chaicharoen S, Poolsup N, Chindavijak B, Pootrakul P, Piankijagum A, Schechter AN, Rogers GP (1996) Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in β-thalassaemia/hemoglobin E disease. Blood 87:887-892
10. Hoppe C, Vichinsky E, Lewis B, Foote D, Styles L (1999) Hydroxyurea and sodium phenylbutyrate therapy in thalassaemia intermedia. Am J Hematol 62:221-227
11. Huang SZ, Ren ZR, Chen MJ, Xu HP, Zeng YT, Rodgers GP, Zeng FY, Schechter AN (1994) Treatment of β-thalassaemia with hydroxyurea (HU) - effect of HU on globin gene expression. Sci China 37:1350-1359
12. Kinney TR, Helme RW, O'Brabski EE, Ohene-Frempong K, Wang W, Daeschner C, et al. (1999) Safety of hydroxyurea in children with sickle-cell anemia: results of the HUG-KIDS study. A phase I/II trial. Blood 94:1550-1554
13. Loukopoulos D, Voskaridou E, Stamoulakatou A, Pappassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N (1998) Hydroxyurea therapy in thalassaemia. Ann N Y Acad Sci 850:120-128
14. Najmabadi H, Karimi-Nejad R, Sahebjam S, Pourfarzad F, Teimourian Sh, Sahebjam F, Amirizadeh N, Karimi-Nejad MH (2001) The β-thalassaemia mutation spectrum in the Iranian population Hemoglobin 25:285-296
15. Olivieri NF (1998) Thalassaemia: clinical management. Bailliere's Clin Haematol 11:147-162
16. Olivieri NF, Rees DC, Ginder GD,Thein SL, Waye JS, Chang L, Brittenham GM, Weatherall DJ (1998) Elimination of transfusions through induction of fetal hemoglobin synthesis in Cooley's anemia. Ann N Y Acad Sci 850:100-109
17. Olivieri NF, Weatheral DJ (1998) The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet 7:1655-1658
18. Rachmielewitz EA, Aker M (1998) The role of recombinant human erythropoetin in the treatment of thalassaemia. Ann N Y Acad Sci 850:129-138
19. Rodgers GP (1998) Pharmacological therapy. Bailliere's Clin Haematol 11:239-255
20. Rodgers GP, Saunthararajah Y (2000) Advances in experimental treatment of beta-thalassaemia. Expert Opin Investig Drugs 10:925-934
21. Rund D, Rachmilewitz E (2000) New trends in the treatment of β-thalassaemia. Crit Rev Oncol Hematol 33:105-118
22. Steinberg MH, Rodgers GP (2001) Pharmacological modulation of fetal hemoglobin. Medicine 80:328-344
23. Vichinsky EP, Lubin BH (1994) A cautionary note regarding hydroxyurea in sickle cell disease. Blood 83:1124-1128
24. Wang WC, Wyun LW, Rogers ZR, Scott JP, Lane PA, Ware RE (2001) A two year trial of hydroxyurea in very young children with sickle cell anemia. J Ped 139:790-796
25. Zeng YT, Huang SZ, Ren ZR, Lu ZH, Zeng FY, Schechter AN, Rogers GP (1995) Hydroxyurea therapy in β-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis. Br J Haematol 90:557-563